Health

Paxlovid 15-Day Regimen Shows No Clear Benefit for Long COVID, Study Finds

Jun 7, 2024 1 min read

Jump to Summary

A clinical trial conducted by Stanford Medicine has found that a 15-day course of Paxlovid, an antiviral drug targeting SARS-CoV-2, does not significantly alleviate symptoms of long COVID. The study, which involved 155 participants, showed no substantial improvement in symptoms such as fatigue, brain fog, shortness of breath, body aches, or gastrointestinal and cardiovascular issues. Despite this, the trial confirmed the safety of an extended-duration Paxlovid treatment.

Published in JAMA Internal Medicine, the findings indicate that while Paxlovid is safe for extended use, it does not reduce long COVID symptoms. Researchers, including Dr. Upinder Singh, suggest that further studies might explore the efficacy of different dosages or treatment durations, or focus on patients with specific symptoms or those who have been ill for shorter periods. Pfizer has stated that these results will not affect their ongoing collaborative studies of Paxlovid as a potential COVID-19 treatment.

#coronavirus #academia #data #tech

Summary

Other news in health

Listeria Scare Leads to Nationwide Produce Recall in Major Supermarkets

Listeria Scare Leads to Nationwide Produce Recall in Major Supermarkets

Wiers Farm Inc. has expanded its recall of produce due to potential listeria contamination. The recall initially included whole and salad cucumbers sold at Walmart stores in Michigan, Indiana, and Ohio. The expanded recall now covers additional vegetables, including green bell peppers, pickling cucumbers, green beans, yellow squash, zucchini, and

Experts Warn of Severe Illness Amid Surge in Covid-19 Cases and New Symptoms

Experts Warn of Severe Illness Amid Surge in Covid-19 Cases and New Symptoms

Health experts in Ireland have issued a major health alert following a rise in COVID-19 cases, which has resulted in an increase in severe disease. The Health Protection Surveillance Centre (HPSC) reported 981 cases in the week leading up to July 6, with 982 cases confirmed in week 29. This

Tenet Healthcare Q2 Earnings and Revenue Beat Estimates, Raises FY24 Guidance

Tenet Healthcare Q2 Earnings and Revenue Beat Estimates, Raises FY24 Guidance

Tenet Healthcare Corp. (NYSE: THC) reported a second-quarter profit of $259 million, or $2.64 per share, a significant increase from the $123 million, or $1.15 per share, reported in the same period last year. Adjusted earnings for the quarter were $226 million, or $2.31 per share. Revenue

Thailand Set to Regulate Medical Cannabis Use

Thailand Set to Regulate Medical Cannabis Use

Thailand's Deputy Prime Minister, Anutin Charnvirakul, has announced plans to regulate the cannabis industry through legislation, focusing on its medical use. This marks a significant shift from previous plans to re-criminalize the plant. Thailand decriminalized cannabis in 2022, becoming one of the first countries in Asia to do